top_banner
Cancer News

Recent Melanoma News
FDA Approves Keytruda for Adjuvant Treatment of Melanoma (March 4, 2019)

On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete... Continue Reading

Isatuximab – Promising for Treatment of Myeloma (February 25, 2019)

A phase 3 comparative clinical trial evaluating Isatuximab has met the primary endpoint of delaying cancer progression in patients with relapsed/refractory multiple myeloma. Multiple myeloma is the second... Continue Reading

Keytruda Approved for Treatment of Stage III Melanoma (February 21, 2019)

The U.S. Food and Drug Administration (FDA) has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete surgical resection. Adjuvant... Continue Reading

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma (January 25, 2019)

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile. CHICAGO (January 25, 2019): Injection of a genetically... Continue Reading

Targeted Combination Treatment for Melanoma now Available (September 10, 2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or... Continue Reading

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring (August 17, 2018)

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher... Continue Reading

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma (May 7, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma... Continue Reading

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma (April 5, 2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival... Continue Reading

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (January 15, 2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1... Continue Reading

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma (January 12, 2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with... Continue Reading

Next Page »